Sanara MedTech stock faces an October 15 merger deadline after vote
Published on 10/07/2026 at 03:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanara MedTech stock was last at USD 35 on Nasdaq on October 6, 2026, placing the share 0.96 percent below its 52-week high of USD 35.34. The central corporate event is the approved MiMedx merger, but regulatory timing still determines when the transaction can close.
Merger vote clears a key hurdle
According to StockTitan in its September 30, 2026 filing summary, shareholders approved the merger proposal and an advisory compensation proposal at the special meeting.
The vote involved 6,411,427 shares, representing 69.78 percent of the 9,188,035 shares outstanding on the September 1, 2026 record date. Proposal 1 received 6,372,989 votes for, compared with 1,944 against and 36,494 abstentions, according to StockTitan.
Regulatory date sets the next checkpoint
The Hart-Scott-Rodino waiting period began again after MiMedx and Sanara refiled their notification on September 15, 2026. The period is scheduled to expire at 11:59 p.m. ET on October 15, 2026, unless extended or ended early, and the merger remains subject to other conditions, according to StockTitan.
That timetable gives the transaction a defined regulatory checkpoint rather than an immediate closing date. For investors, the merger process is therefore the main company-specific variable while the share price remains close to its yearly peak.
Second-quarter revenue reached USD 28.14 million
Sanara reported USD 28.14 million in revenue for the quarter ended June 2026, up from USD 25.83 million a year earlier. According to Zacks on August 11, 2026, the increase was paired with adjusted EPS of USD 0.05, above the USD 0.02 consensus estimate.
The revenue result missed the Zacks consensus estimate of USD 29.40 million by 4.3 percent, creating a mixed quarterly picture. The company operates in wound care, surgical reconstruction and tissue repair, according to MarketBeat.
Consensus target matches the Nasdaq quote
MarketBeat reported on September 26, 2026, that five brokerages assigned Sanara an average Reduce rating and a 12-month consensus target of USD 35.00. The target matches the USD 35 Nasdaq price used here, while the reported 52-week range runs from USD 16.05 to USD 35.34.
Nasdaq quote stays below yearly high
Sanara MedTech stock was last at USD 35 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with a market capitalization of USD 321.8 million and volume of 155,590 shares. The 52-week range is USD 16.05 to USD 35.34, leaving the price 0.96 percent below the high.
Sanara MedTech stock facts
- Company: Sanara MedTech Inc.
- ISIN: US79957L1008
- WKN: A2PKM6
- Ticker: SMTI
- Trading venue: Nasdaq
- Price (as of October 6, 2026, 4:00 p.m. ET): USD 35
- Market capitalization: USD 321.8 million (as of October 6, 2026)
- 52-week range: USD 16.05-35.34
- Sector / Industry: Healthcare / Medical Instruments and Supplies
Upcoming dates for Sanara MedTech stock
- October 15, 2026: Hart-Scott-Rodino waiting period expiration
